Loading
PDBj
メニューPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7WD1

Crystal structure of R14 bound to SARS-CoV-2 RBD

7WD1 の概要
エントリーDOI10.2210/pdb7wd1/pdb
分子名称Spike protein S1, R14, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, ... (5 entities in total)
機能のキーワードsars-cov-2, rbd, nanobody, complex, viral protein
由来する生物種Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2)
詳細
タンパク質・核酸の鎖数4
化学式量合計73098.20
構造登録者
Wang, Q.H.,Gao, G.F.,Qi, J.X.,Su, C.,Liu, H.H.,Wu, L.L. (登録日: 2021-12-20, 公開日: 2022-12-21, 最終更新日: 2023-11-29)
主引用文献Liu, H.,Wu, L.,Liu, B.,Xu, K.,Lei, W.,Deng, J.,Rong, X.,Du, P.,Wang, L.,Wang, D.,Zhang, X.,Su, C.,Bi, Y.,Chen, H.,Liu, W.J.,Qi, J.,Cui, Q.,Qi, S.,Fan, R.,Jiang, J.,Wu, G.,Gao, G.F.,Wang, Q.
Two pan-SARS-CoV-2 nanobodies and their multivalent derivatives effectively prevent Omicron infections in mice.
Cell Rep Med, 4:100918-100918, 2023
Cited by
PubMed Abstract: With the widespread vaccinations against coronavirus disease 2019 (COVID-19), we are witnessing gradually waning neutralizing antibodies and increasing cases of breakthrough infections, necessitating the development of drugs aside from vaccines, particularly ones that can be administered outside of hospitals. Here, we present two cross-reactive nanobodies (R14 and S43) and their multivalent derivatives, including decameric ones (fused to the immunoglobulin M [IgM] Fc) that maintain potent neutralizing activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after aerosolization and display not only pan-SARS-CoV-2 but also varied pan-sarbecovirus activities. Through respiratory administration to mice, monovalent and decameric R14 significantly reduce the lung viral RNAs at low dose and display potent pre- and post-exposure protection. Furthermore, structural studies reveal the neutralizing mechanisms of R14 and S43 and the multiple inhibition effects that the multivalent derivatives exert. Our work demonstrates promising convenient drug candidates via respiratory administration against SARS-CoV-2 infection, which can contribute to containing the COVID-19 pandemic.
PubMed: 36702124
DOI: 10.1016/j.xcrm.2023.100918
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.5 Å)
構造検証レポート
Validation report summary of 7wd1
検証レポート(詳細版)ダウンロードをダウンロード

226707

件を2024-10-30に公開中

PDB statisticsPDBj update infoContact PDBjnumon